Novo Nordisk's Pipeline Wins Meet a Market Still Searching for a Floor

Novo Nordisk stock is down 25% this year as FDA review of Denecimig drags on, Lilly rivalry builds, and CagriSema data offers pipeline hope.

Novo Nordisk finds itself navigating a tricky stretch. On one side, the Danish drugmaker is pushing its clinical pipeline forward with fresh trial readouts and licensing deals; on the other, regulatory holdups and mounting pressure from US rival Eli Lilly are weighing on sentiment. Shares closed Friday at EUR 33.06, leaving the stock down 25% since the start of the year and roughly 40% below its 52-week high.

That gap tells its own story about investor caution. Pressure on management is building as patent expirations edge closer and competitors close in. The company has reaffirmed its ability to develop new blockbusters, yet many investors remain wary of the phase that follows the current obesity-drug boom. The debate now centers on future pricing power and the pace of new therapies.

A Capital Markets Day That Didn't Reassure

Roughly two weeks ago, the company's capital markets day landed with a thud, and the stock has shed 5.1% since. At one point the shares fell as much as 9%. According to Reuters, the long-term targets did little to ease concerns about near-term growth.

Central to those discussions was how Novo Nordisk intends to secure growth ahead of looming patent expirations. Management reiterated plans to massively expand capacity for oral formulations and to reach significantly more patients worldwide. The long-term targets for 2030 are, by the company's own account, strategic ambitions rather than a financial forecast.

On September 22, research firm CFRA downgraded Novo Nordisk's US depositary receipts from Hold to Sell, setting a price target of $38. The analysts cited an unfavorable risk-reward profile during a transition phase following peak earnings for GLP-1 drugs, along with intensifying competition.

FDA Review of Denecimig Drags On

Friday brought word that the US Food and Drug Administration is still reviewing the hemophilia A candidate Denecimig. No new decision timeline has been set. The delay stems from remediation work at a manufacturing site. According to the company, the agency did not flag any clinical shortcomings in efficacy or safety.

The holdup does not affect the financial outlook for 2026, Novo Nordisk said. Subject to regulatory approval, the company is still targeting a US market launch for Denecimig in the first half of 2027. The waiting game underscores just how critical reliable manufacturing processes are to bringing new treatments to market.

Betting on External Science

To shore up its position, the company is also looking outside its own labs. On Tuesday, Novo Nordisk struck an exclusive licensing agreement with Hengrui Pharma for the drug candidate HRS-1596, a substance still in the pre-clinical phase.

The deal covers global rights outside mainland China, Hong Kong, Macau and Taiwan. Novo Nordisk will pay $300 million upfront, with the total potential transaction value reaching up to $2.6 billion, plus royalties for Hengrui. Completion is expected in the fourth quarter of 2026, subject to regulatory clearances, including antitrust approval in the US.

Expanding oral formulations is a deliberate response to shifting patient preferences. The market for metabolic therapies is moving away from injections toward easy-to-take tablets, and management is working to bring new molecules on board early to defend its long-term position in metabolic disease.

CagriSema and Wegovy Data Underpin the Portfolio

On the scientific front, the company reinforced its progress at the annual EASD meeting. On Wednesday, Novo Nordisk presented data on development candidate CagriSema. In one study, the drug achieved a 22.4% reduction in body weight versus placebo after 52 weeks.

In the Phase 3 REIMAGINE 5 trial, CagriSema produced 12.4% weight loss in adults with type 2 diabetes, compared with 9.1% for tirzepatide. The REDEFINE 9 study showed a 21% reduction in body weight versus placebo.

Additional analyses pointed to meaningful declines in organ fat, particularly in the liver and pancreas. Other results suggest the drug may curb food cravings and reduce organ fat. For Novo Nordisk, this broader therapeutic evidence is a key argument in the battle for market share against Eli Lilly and other rivals.

Separately, an evaluation presented Thursday showed positive effects of Wegovy on the liver. In the vast majority of participants studied, liver fat fell into the normal range after 72 weeks. The mean fat value dropped from 8.8% to 3.1%.

Data released Wednesday also documented weight loss after patients switched from injectable therapies to oral Wegovy. Novo Nordisk is using these results to shore up its therapeutic base.

What happens next on the stock hinges largely on how quickly manufacturing problems are resolved and how the rivalry with Eli Lilly plays out. Market participants, for now, are watching above all for reliable operational execution of the growth plans.